Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Esomeprazole (Nexium® IV) is recommended as an option for use within NHS Wales for gastric antisecretory treatment when the oral route is not possible, such as gastro-oesophageal reflux disease (GORD) in patients with erosive reflux oesophagitis and/or severe symptoms of reflux for children and adolescents aged 1–18 years of age. AWMSG is of the opinion that esomeprazole (Nexium® IV) is suitable for specialist only prescribing within NHS Wales for the above indication. |
|||
|
|||
Medicine details |
|||
| Medicine name | esomeprazole (Nexium®) | ||
| Formulation | 40 mg powder for solution for injection / infusion | ||
| Reference number | 1185 | ||
| Indication | Gastric antisecretory treatment when the oral route is not possible, such as gastro-oesophageal reflux disease (GORD) in patients with erosive reflux oesophagitis and/or severe symptoms of reflux for children and adolescents aged 1-18 years of age |
||
| Company | AstraZeneca UK Ltd | ||
| BNF chapter | Gastro-intestinal system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0712 | ||
| NMG meeting date | 21/02/2012 | ||
| AWMSG meeting date | 21/03/2012 | ||
| Ratification by Welsh Government | 25/04/2012 | ||
| Date of issue | 01/05/2012 | ||
| Date of last review | 30/09/2016 | ||